Communiqués Perspective Therapeutics, Inc.

Actions

CATX

US46489V3024

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 21:40:14 08/07/2026			Varia. 5j.	Varia. 1 janv.
3,380 ^USD	-1,17 %		-1,73 %	+23,64 %

19:07	Perspective Therapeutics, Inc. annonce des changements au sein de sa direction	CI
13:14	Perspective Therapeutics nomme Paul Lyne au poste de directeur scientifique, le cofondateur Michael Schultz devient conseiller	MT

Communiqués

12:30	Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor	AQ
03/06	Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study	AQ
21/05	Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma	AQ
18/05	Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies	AQ
11/05	Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2026 Results	AQ
24/04	Perspective Therapeutics to Provide Several Upcoming Corporate Updates	AQ
20/04	Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting	AQ
02/04	Perspective Therapeutics to Participate in Upcoming Investor Conferences	AQ
17/03	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026	AQ
16/03	Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results	AQ
17/02	Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results	AQ
02/02	Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants	AQ
12/01	Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference	AQ
09/01	Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium	AQ
18/12	Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
04/12	Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium	AQ
20/11	Perspective Therapeutics to Participate in Upcoming December Conferences	AQ
10/11	Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results	AQ
31/10/25	Perspective Therapeutics to Participate in Upcoming November Conferences	AQ
24/10/25	Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results	AQ
20/10/25	Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the ESMO Congress 2025	AQ
02/10/25	Perspective Therapeutics Announces First Patient Dosed with PSV359 in the Second Cohort of a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors	AQ
15/09/25	Perspective Therapeutics Progresses Dose Finding for [212Pb]VMT01 in Combination with Nivolumab in its Ongoing Phase 1/2a Study of MC1R-Positive Metastatic Melanoma	AQ
04/09/25	Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer	AQ
03/09/25	Perspective Therapeutics Appoints Maya Martinez-Davis to Board of Directors	AQ